We are live on ! Find out more
RCMNY

Rubric Capital Management (New York) Portfolio holdings

AUM $9.44B
1-Year Est. Return 68.42%
This Fund
S&P 500
This Quarter Est. Return
+25.86%
1 Year Est. Return
+68.42%
3 Year Est. Return
+212.09%
5 Year Est. Return
+270.59%
10 Year Est. Return
AUM
$8.86B
AUM Growth
+$2.24B
Cap. Flow
+$911M
Cap. Flow %
10.28%
Top 10 Hldgs %
59.7%
Holding
84
New
18
Increased
19
Reduced
9
Closed
12

Sector Composition

Rank Sector Weight
1 Healthcare 31.07%
2 Utilities 21%
3 Industrials 12.9%
4 Energy 5.78%
5 Financials 3.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
LILAK icon
26
Liberty Latin America Class C
LILAK
$1.67B
$86.6M 0.98%
+11,282,629
New +$77M
BAX icon
27
Baxter International
BAX
$14.1B
$86M 0.97%
+3,774,889
New +$95.7M
ENOV icon
28
Enovis
ENOV
$1.41B
$83.4M 0.94%
+2,750,000
New +$83.4M
ZYME icon
29
Zymeworks
ZYME
$1.77B
$80.5M 0.91%
4,710,551
TRVI icon
30
Trevi Therapeutics
TRVI
$2.51B
$78.1M 0.88%
8,531,860
CMPR icon
31
Cimpress
CMPR
$2.35B
$74.4M 0.84%
1,180,789
+619,360
+110% +$34.7M
OPK icon
32
Opko Health
OPK
$1.04B
$74.1M 0.84%
47,791,243
ADEA icon
33
Adeia
ADEA
$3.12B
$72M 0.81%
4,284,205
NWL icon
34
Newell Brands
NWL
$2.61B
$68.1M 0.77%
+13,000,000
New +$73.7M
TDS icon
35
Telephone and Data Systems
TDS
$3.82B
$62.8M 0.71%
+1,600,000
New +$61.6M
MNKD icon
36
MannKind Corp
MNKD
$1.25B
$61.3M 0.69%
+11,414,671
New +$50.1M
GEO icon
37
The GEO Group
GEO
$4.1B
$61.2M 0.69%
2,986,915
+1,739,522
+139% +$39.7M
PRLB icon
38
Protolabs
PRLB
$2.18B
$56.2M 0.63%
1,123,338
+89,167
+9% +$4.09M
NFE icon
39
New Fortress Energy
NFE
$92.6M
$54.7M 0.62%
24,767,087
+367,087
+2% +$1.04M
OFIX icon
40
Orthofix Medical
OFIX
$416M
$54.5M 0.61%
3,721,715
LBTYK icon
41
Liberty Global Class C
LBTYK
$3.45B
$53.3M 0.6%
4,538,570
+1,248,781
+38% +$14M
SPRY icon
42
ARS Pharmaceuticals
SPRY
$594M
$45.2M 0.51%
4,500,000
+3,205,122
+248% +$46M
MATV icon
43
Mativ Holdings
MATV
$687M
$45M 0.51%
3,982,442
CXW icon
44
CoreCivic
CXW
$3.31B
$39.9M 0.45%
1,961,446
+1,146,166
+141% +$23.7M
ALIT icon
45
Alight
ALIT
$370M
$37.2M 0.42%
569,929
-411,419
-42% -$36.3M
HRTX icon
46
Heron Therapeutics
HRTX
$65.8M
$36.7M 0.41%
29,100,728
+2,387,225
+9% +$3.78M
MREO
47
Mereo BioPharma
MREO
$47.6M
$31.5M 0.36%
15,307,347
ANIP icon
48
ANI Pharmaceuticals
ANIP
$1.72B
$31.5M 0.35%
343,414
+85,745
+33% +$6.99M
MGTX icon
49
MeiraGTx Holdings
MGTX
$1.2B
$30.7M 0.35%
3,726,451
SCPH
50
DELISTED
scPharmaceuticals
SCPH
$28.9M 0.33%
5,101,886
+499,909
+11% +$2.56M

Similar funds

Rubric Capital Management (New York)'s Q3 2025 Portfolio in Review

As of Q3 2025, Rubric Capital Management (New York) held 84 positions worth $8.86B, up 34% from $6.62B the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Rubric Capital Management (New York) deployed $911M of net new capital in Q3 2025, opening 18 new positions and adding to 19 existing holdings. Its largest new stake was Baxter International: 3,774,889 shares worth $86M.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 32% a quarter earlier, followed by Utilities and Industrials.

On the sell side, the largest reduction was Talen Energy Corp, an estimated $326M trimmed.

  • Rubric Capital Management (New York)'s largest Q3 2025 buy was Baxter International: 3,774,889 shares worth $86M.
  • Rubric Capital Management (New York) added most to Ecovyst in Q3 2025, an estimated $50.2M increase.
  • Rubric Capital Management (New York)'s biggest Q3 2025 reduction was Talen Energy Corp, cutting an estimated $326M.
  • Rubric Capital Management (New York) fully exited Vistra in Q3 2025, selling an estimated $276M.
  • Rubric Capital Management (New York)'s ten largest holdings make up 60% of its $8.86B portfolio in Q3 2025.
  • Rubric Capital Management (New York) opened 18 new positions and closed 12 in Q3 2025.
  • Rubric Capital Management (New York)'s portfolio value rose 34% quarter-over-quarter to $8.86B.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2025, filed 14 Nov 2025.